vs
Side-by-side financial comparison of HEARTLAND EXPRESS INC (HTLD) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
HEARTLAND EXPRESS INC is the larger business by last-quarter revenue ($179.4M vs $129.7M, roughly 1.4× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs -26.1%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs -18.5%).
Heartland Express is an American trucking company headquartered in North Liberty, Iowa. The company offers truckload shipping services across the United States.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
HTLD vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $179.4M | $129.7M |
| Net Profit | $-19.4M | — |
| Gross Margin | — | 98.0% |
| Operating Margin | -12.7% | -25.0% |
| Net Margin | -10.8% | — |
| Revenue YoY | -26.1% | 73.4% |
| Net Profit YoY | -949.2% | — |
| EPS (diluted) | $-0.24 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $179.4M | $129.7M | ||
| Q3 25 | $196.5M | $164.9M | ||
| Q2 25 | $210.4M | $114.4M | ||
| Q1 25 | $219.4M | $81.7M | ||
| Q4 24 | $242.6M | $74.8M | ||
| Q3 24 | $259.9M | $62.9M | ||
| Q2 24 | $274.8M | $54.1M | ||
| Q1 24 | $270.3M | $41.4M |
| Q4 25 | $-19.4M | — | ||
| Q3 25 | $-8.3M | $25.7M | ||
| Q2 25 | $-10.9M | $-12.8M | ||
| Q1 25 | $-13.9M | $-41.2M | ||
| Q4 24 | $-1.9M | — | ||
| Q3 24 | $-9.3M | $-54.8M | ||
| Q2 24 | $-3.5M | $-70.4M | ||
| Q1 24 | $-15.1M | $-136.1M |
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% | ||
| Q1 24 | — | 96.4% |
| Q4 25 | -12.7% | -25.0% | ||
| Q3 25 | -3.7% | 15.1% | ||
| Q2 25 | -5.9% | -11.1% | ||
| Q1 25 | -6.8% | -52.2% | ||
| Q4 24 | 0.4% | -81.2% | ||
| Q3 24 | -2.7% | -89.3% | ||
| Q2 24 | 0.1% | -125.1% | ||
| Q1 24 | -5.3% | -336.5% |
| Q4 25 | -10.8% | — | ||
| Q3 25 | -4.2% | 15.6% | ||
| Q2 25 | -5.2% | -11.1% | ||
| Q1 25 | -6.3% | -50.4% | ||
| Q4 24 | -0.8% | — | ||
| Q3 24 | -3.6% | -87.1% | ||
| Q2 24 | -1.3% | -130.1% | ||
| Q1 24 | -5.6% | -328.9% |
| Q4 25 | $-0.24 | $0.04 | ||
| Q3 25 | $-0.11 | $0.28 | ||
| Q2 25 | $-0.14 | $-0.14 | ||
| Q1 25 | $-0.18 | $-0.47 | ||
| Q4 24 | $-0.03 | $-0.71 | ||
| Q3 24 | $-0.12 | $-0.70 | ||
| Q2 24 | $-0.04 | $-0.91 | ||
| Q1 24 | $-0.19 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.5M | $93.0M |
| Total DebtLower is stronger | $154.1M | — |
| Stockholders' EquityBook value | $755.3M | $114.8M |
| Total Assets | $1.2B | $605.2M |
| Debt / EquityLower = less leverage | 0.20× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.5M | $93.0M | ||
| Q3 25 | $32.7M | $110.9M | ||
| Q2 25 | $22.9M | $75.2M | ||
| Q1 25 | $23.9M | $61.9M | ||
| Q4 24 | $12.8M | $58.5M | ||
| Q3 24 | $30.7M | $36.4M | ||
| Q2 24 | $23.9M | $32.3M | ||
| Q1 24 | $23.8M | $43.3M |
| Q4 25 | $154.1M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $187.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $755.3M | $114.8M | ||
| Q3 25 | $775.6M | $73.6M | ||
| Q2 25 | $786.7M | $32.7M | ||
| Q1 25 | $807.7M | $32.8M | ||
| Q4 24 | $822.6M | $59.1M | ||
| Q3 24 | $825.7M | $-30.5M | ||
| Q2 24 | $836.8M | $15.1M | ||
| Q1 24 | $848.8M | $74.1M |
| Q4 25 | $1.2B | $605.2M | ||
| Q3 25 | $1.3B | $538.6M | ||
| Q2 25 | $1.3B | $555.3M | ||
| Q1 25 | $1.3B | $548.8M | ||
| Q4 24 | $1.3B | $594.1M | ||
| Q3 24 | $1.4B | $504.4M | ||
| Q2 24 | $1.4B | $551.1M | ||
| Q1 24 | $1.5B | $663.5M |
| Q4 25 | 0.20× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.23× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.9M | $60.7M |
| Free Cash FlowOCF − Capex | $-44.2M | — |
| FCF MarginFCF / Revenue | -24.6% | — |
| Capex IntensityCapex / Revenue | 33.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-66.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.9M | $60.7M | ||
| Q3 25 | $27.5M | $14.3M | ||
| Q2 25 | $21.0M | $5.0M | ||
| Q1 25 | $25.8M | $-42.2M | ||
| Q4 24 | $37.8M | $-35.7M | ||
| Q3 24 | $35.6M | $-42.5M | ||
| Q2 24 | $40.0M | $-40.2M | ||
| Q1 24 | $31.0M | $-119.0M |
| Q4 25 | $-44.2M | — | ||
| Q3 25 | $-12.2M | $14.2M | ||
| Q2 25 | $-12.8M | — | ||
| Q1 25 | $2.3M | — | ||
| Q4 24 | $-45.5M | — | ||
| Q3 24 | $24.6M | — | ||
| Q2 24 | $29.4M | $-40.3M | ||
| Q1 24 | $26.3M | — |
| Q4 25 | -24.6% | — | ||
| Q3 25 | -6.2% | 8.6% | ||
| Q2 25 | -6.1% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | -18.8% | — | ||
| Q3 24 | 9.5% | — | ||
| Q2 24 | 10.7% | -74.5% | ||
| Q1 24 | 9.7% | — |
| Q4 25 | 33.0% | — | ||
| Q3 25 | 20.2% | 0.1% | ||
| Q2 25 | 16.1% | — | ||
| Q1 25 | 10.7% | — | ||
| Q4 24 | 34.3% | — | ||
| Q3 24 | 4.2% | 0.0% | ||
| Q2 24 | 3.8% | 0.2% | ||
| Q1 24 | 1.7% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HTLD
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
